메뉴 건너뛰기




Volumn 15, Issue 1, 2015, Pages

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

Author keywords

Antiestrogen resistance; Aurora kinase B; Barasertib; Breast cancer; Fulvestrant; Tamoxifen

Indexed keywords

ANTIESTROGEN; AURORA A KINASE; AURORA B KINASE; BARASERTIB; BIOLOGICAL MARKER; CELL PROTEIN; ESTROGEN RECEPTOR; FULVESTRANT; HESPERADIN; HISTONE H3; INNER CENTROMERE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TAMOXIFEN; UNCLASSIFIED DRUG; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ORGANOPHOSPHATE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

EID: 84926679232     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1210-4     Document Type: Article
Times cited : (22)

References (49)
  • 1
    • 79551576468 scopus 로고    scopus 로고
    • Mechanisms of endocrine resistance in breast cancer
    • Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
    • (2011) Annu Rev Med , vol.62 , pp. 233-247
    • Osborne, C.K.1    Schiff, R.2
  • 2
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
    • Ebctcg, Ebctcg: Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 3
    • 0028861402 scopus 로고
    • Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
    • Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995;345:29-30.
    • (1995) Lancet , vol.345 , pp. 29-30
    • Howell, A.1    DeFriend, D.2    Robertson, J.3    Blamey, R.4    Walton, P.5
  • 4
    • 0034663421 scopus 로고    scopus 로고
    • ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen
    • Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000;89:817-25.
    • (2000) Cancer , vol.89 , pp. 817-825
    • Howell, A.1    Osborne, C.K.2    Morris, C.3    Wakeling, A.E.4
  • 5
    • 0038683988 scopus 로고    scopus 로고
    • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    • Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229-38.
    • (2003) Cancer , vol.98 , pp. 229-238
    • Robertson, J.F.1    Osborne, C.K.2    Howell, A.3    Jones, S.E.4    Mauriac, L.5    Ellis, M.6
  • 7
    • 69249137029 scopus 로고    scopus 로고
    • Biological determinants of endocrine resistance in breast cancer
    • Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:631-43.
    • (2009) Nat Rev Cancer , vol.9 , pp. 631-643
    • Musgrove, E.A.1    Sutherland, R.L.2
  • 8
    • 0028329961 scopus 로고
    • Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1
    • Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994;54:1587-95.
    • (1994) Cancer Res , vol.54 , pp. 1587-1595
    • Lykkesfeldt, A.E.1    Madsen, M.W.2    Briand, P.3
  • 9
    • 0029059562 scopus 로고
    • Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment
    • Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer. 1995;61:529-34.
    • (1995) Int J Cancer , vol.61 , pp. 529-534
    • Lykkesfeldt, A.E.1    Larsen, S.S.2    Briand, P.3
  • 10
    • 0031051458 scopus 로고    scopus 로고
    • Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells
    • Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res. 1997;57:585-9.
    • (1997) Cancer Res , vol.57 , pp. 585-589
    • Madsen, M.W.1    Reiter, B.E.2    Larsen, S.S.3    Briand, P.4    Lykkesfeldt, A.E.5
  • 11
    • 84893698272 scopus 로고    scopus 로고
    • T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant
    • Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sorensen BS, Lykkesfeldt AE. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014;344:90-100.
    • (2014) Cancer Lett , vol.344 , pp. 90-100
    • Kirkegaard, T.1    Hansen, S.K.2    Larsen, S.L.3    Reiter, B.E.4    Sorensen, B.S.5    Lykkesfeldt, A.E.6
  • 12
    • 59449093537 scopus 로고    scopus 로고
    • Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    • Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 2009;114:263-75.
    • (2009) Breast Cancer Res Treat , vol.114 , pp. 263-275
    • Frogne, T.1    Benjaminsen, R.V.2    Sonne-Hansen, K.3    Sorensen, B.S.4    Nexo, E.5    Laenkholm, A.V.6
  • 13
    • 77953119642 scopus 로고    scopus 로고
    • Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
    • Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, et al. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat. 2010;121:601-13.
    • (2010) Breast Cancer Res Treat , vol.121 , pp. 601-613
    • Sonne-Hansen, K.1    Norrie, I.C.2    Emdal, K.B.3    Benjaminsen, R.V.4    Frogne, T.5    Christiansen, I.J.6
  • 14
    • 84877582872 scopus 로고    scopus 로고
    • Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling
    • Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 2013;139:71-80.
    • (2013) Breast Cancer Res Treat , vol.139 , pp. 71-80
    • Thrane, S.1    Lykkesfeldt, A.E.2    Larsen, M.S.3    Sorensen, B.S.4    Yde, C.W.5
  • 15
    • 58249105933 scopus 로고    scopus 로고
    • ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and p90RSK
    • Pancholi S, Lykkesfeldt A, Hilmi C, Banerjee S, Leary A, Drury S, et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and p90RSK. EndocrRelat Cancer. 2008;15:985-1002.
    • (2008) EndocrRelat Cancer , vol.15 , pp. 985-1002
    • Pancholi, S.1    Lykkesfeldt, A.2    Hilmi, C.3    Banerjee, S.4    Leary, A.5    Drury, S.6
  • 16
    • 0037534310 scopus 로고    scopus 로고
    • Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines
    • Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol. 2003;85:33-47.
    • (2003) J Steroid Biochem Mol Biol , vol.85 , pp. 33-47
    • Sommer, A.1    Hoffmann, J.2    Lichtner, R.B.3    Schneider, M.R.4    Parczyk, K.5
  • 17
    • 0034987631 scopus 로고    scopus 로고
    • Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
    • McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. 2001;142:2776-88.
    • (2001) Endocrinology , vol.142 , pp. 2776-2788
    • McClelland, R.A.1    Barrow, D.2    Madden, T.A.3    Dutkowski, C.M.4    Pamment, J.5    Knowlden, J.M.6
  • 18
    • 38849091433 scopus 로고    scopus 로고
    • Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
    • Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68:826-33.
    • (2008) Cancer Res , vol.68 , pp. 826-833
    • Massarweh, S.1    Osborne, C.K.2    Creighton, C.J.3    Qin, L.4    Tsimelzon, A.5    Huang, S.6
  • 19
    • 37049183697 scopus 로고
    • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 20
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 22
    • 84870192369 scopus 로고    scopus 로고
    • The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
    • Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 2012;13:789-803.
    • (2012) Nat Rev Mol Cell Biol , vol.13 , pp. 789-803
    • Carmena, M.1    Wheelock, M.2    Funabiki, H.3    Earnshaw, W.C.4
  • 23
    • 33846809037 scopus 로고    scopus 로고
    • DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains
    • Monier K, Mouradian S, Sullivan KF. DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci. 2007;120:101-14.
    • (2007) J Cell Sci , vol.120 , pp. 101-114
    • Monier, K.1    Mouradian, S.2    Sullivan, K.F.3
  • 25
  • 26
    • 70249098518 scopus 로고    scopus 로고
    • Clinical experience with aurora kinase inhibitors: a review
    • Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009;14:780-93.
    • (2009) Oncologist , vol.14 , pp. 780-793
    • Boss, D.S.1    Beijnen, J.H.2    Schellens, J.H.3
  • 29
    • 0034866694 scopus 로고    scopus 로고
    • Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways
    • Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 2001;67:199-214.
    • (2001) Breast Cancer Res Treat , vol.67 , pp. 199-214
    • Lundholt, B.K.1    Briand, P.2    Lykkesfeldt, A.E.3
  • 30
    • 50649117316 scopus 로고    scopus 로고
    • The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis
    • Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B. The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene. 2008;27:4986-97.
    • (2008) Oncogene , vol.27 , pp. 4986-4997
    • Yde, C.W.1    Olsen, B.B.2    Meek, D.3    Watanabe, N.4    Guerra, B.5
  • 31
    • 34250740430 scopus 로고    scopus 로고
    • Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death
    • Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther. 2007;6:1869-76.
    • (2007) Mol Cancer Ther , vol.6 , pp. 1869-1876
    • Yde, C.W.1    Gyrd-Hansen, M.2    Lykkesfeldt, A.E.3    Issinger, O.G.4    Stenvang, J.5
  • 32
    • 45149090757 scopus 로고    scopus 로고
    • The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
    • Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506-24.
    • (2008) Acta Oncol , vol.47 , pp. 506-524
    • Moller, S.1    Jensen, M.B.2    Ejlertsen, B.3    Bjerre, K.D.4    Larsen, M.5    Hansen, H.B.6
  • 33
    • 67549088394 scopus 로고    scopus 로고
    • Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
    • Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11.
    • (2009) Breast Cancer Res , vol.11 , pp. R11
    • Frogne, T.1    Laenkholm, A.V.2    Lyng, M.B.3    Henriksen, K.L.4    Lykkesfeldt, A.E.5
  • 34
    • 0034604354 scopus 로고    scopus 로고
    • Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes
    • Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell. 2000;102:279-91.
    • (2000) Cell , vol.102 , pp. 279-291
    • Hsu, J.Y.1    Sun, Z.W.2    Li, X.3    Reuben, M.4    Tatchell, K.5    Bishop, D.K.6
  • 36
    • 33244490241 scopus 로고    scopus 로고
    • Complex formation of Plk1 and INCENP required for metaphase-anaphase transition
    • Goto H, Kiyono T, Tomono Y, Kawajiri A, Urano T, Furukawa K, et al. Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat Cell Biol. 2006;8:180-7.
    • (2006) Nat Cell Biol , vol.8 , pp. 180-187
    • Goto, H.1    Kiyono, T.2    Tomono, Y.3    Kawajiri, A.4    Urano, T.5    Furukawa, K.6
  • 37
    • 85027947011 scopus 로고    scopus 로고
    • Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer
    • Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY, et al. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer. Oncogene. 2014;33:4985-96.
    • (2014) Oncogene , vol.33 , pp. 4985-4996
    • Zheng, X.Q.1    Guo, J.P.2    Yang, H.3    Kanai, M.4    He, L.L.5    Li, Y.Y.6
  • 38
    • 84922594316 scopus 로고    scopus 로고
    • Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
    • Hole S, Pedersen AM, Lykkesfeldt AE, Yde CW. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Res Treat. 2015;149:715-26.
    • (2015) Breast Cancer Res Treat , vol.149 , pp. 715-726
    • Hole, S.1    Pedersen, A.M.2    Lykkesfeldt, A.E.3    Yde, C.W.4
  • 39
    • 78649864566 scopus 로고    scopus 로고
    • Aurora kinase inhibitors as anticancer molecules
    • Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta. 2010;1799:829-39.
    • (2010) Biochim Biophys Acta , vol.1799 , pp. 829-839
    • Katayama, H.1    Sen, S.2
  • 40
    • 0037105758 scopus 로고    scopus 로고
    • Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability
    • Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002;62:5168-77.
    • (2002) Cancer Res , vol.62 , pp. 5168-5177
    • Ota, T.1    Suto, S.2    Katayama, H.3    Han, Z.B.4    Suzuki, F.5    Maeda, M.6
  • 41
    • 38349108184 scopus 로고    scopus 로고
    • The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma
    • Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol. 2008;140:295-302.
    • (2008) Br J Haematol , vol.140 , pp. 295-302
    • Evans, R.P.1    Naber, C.2    Steffler, T.3    Checkland, T.4    Maxwell, C.A.5    Keats, J.J.6
  • 42
    • 34250739960 scopus 로고    scopus 로고
    • AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
    • Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007;13:3682-8.
    • (2007) Clin Cancer Res , vol.13 , pp. 3682-3688
    • Wilkinson, R.W.1    Odedra, R.2    Heaton, S.P.3    Wedge, S.R.4    Keen, N.J.5    Crafter, C.6
  • 43
    • 66249093516 scopus 로고    scopus 로고
    • AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo
    • Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009;69:4150-8.
    • (2009) Cancer Res , vol.69 , pp. 4150-4158
    • Oke, A.1    Pearce, D.2    Wilkinson, R.W.3    Crafter, C.4    Odedra, R.5    Cavenagh, J.6
  • 44
    • 84879554441 scopus 로고    scopus 로고
    • Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    • Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2013;31:370-80.
    • (2013) Invest New Drugs , vol.31 , pp. 370-380
    • Schwartz, G.K.1    Carvajal, R.D.2    Midgley, R.3    Rodig, S.J.4    Stockman, P.K.5    Ataman, O.6
  • 45
    • 79251556865 scopus 로고    scopus 로고
    • Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
    • Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011;22:431-7.
    • (2011) Ann Oncol , vol.22 , pp. 431-437
    • Boss, D.S.1    Witteveen, P.O.2    Sar, J.3    Lolkema, M.P.4    Voest, E.E.5    Stockman, P.K.6
  • 46
    • 80052100694 scopus 로고    scopus 로고
    • A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
    • Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, et al. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res. 2011;35:1384-9.
    • (2011) Leuk Res , vol.35 , pp. 1384-1389
    • Tsuboi, K.1    Yokozawa, T.2    Sakura, T.3    Watanabe, T.4    Fujisawa, S.5    Yamauchi, T.6
  • 47
    • 82955217793 scopus 로고    scopus 로고
    • Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
    • Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011;118:6030-6.
    • (2011) Blood , vol.118 , pp. 6030-6036
    • Lowenberg, B.1    Muus, P.2    Ossenkoppele, G.3    Rousselot, P.4    Cahn, J.Y.5    Ifrah, N.6
  • 48
    • 24644497683 scopus 로고    scopus 로고
    • Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor
    • Zheng FF, Wu RC, Smith CL, O'Malley BW. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol Cell Biol. 2005;25:8273-84.
    • (2005) Mol Cell Biol , vol.25 , pp. 8273-8284
    • Zheng, F.F.1    Wu, R.C.2    Smith, C.L.3    O'Malley, B.W.4
  • 49
    • 84862644315 scopus 로고    scopus 로고
    • High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer
    • Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlen ther Onkol. 2012;188:248-54.
    • (2012) Strahlen ther Onkol , vol.188 , pp. 248-254
    • Erpolat, O.P.1    Gocun, P.U.2    Akmansu, M.3    Karakus, E.4    Akyol, G.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.